Overview
Availability
- Dr Jake O'Donnell is:
- Available for supervision
Qualifications
- Bachelor (Honours), The University of Queensland
- Doctor of Philosophy, The University of Queensland
- Masters (Coursework) of Business Administration, Griffith University
Research interests
-
Monoclonal Antibody Development
We have developed a pipeline for rapid flow cytometry and cell-sorting-based development of either mouse or human monoclonal antibodies with potential uses as research tools or therapies.
-
Human T-lymphotropic virus 1 (HTLV-1) and Adult T cell Leukemia/Lymphoma (ATLL)
We have interests in the development of therapies for treatment of HTLV-1 and ATLL using basic research principles and structural biological approaches.
-
Understanding the impacts of vaccine adjuvants on immune responses
We have interests in characterising the impacts that specific antigen/adjuvant pairings have in vaccine development, and how this understanding can guide adjuvant selection in vaccine development
-
The structural basis for anti-retroviral efficacy for novel indications
We have interest in understanding the applicability and potential efficacy of existing and novel anti-retroviral therapies for treatment of different retroviral infections. Our current focuses are on HTLV-1 and Koala Retrovirus.
-
Immunology of koalas, retrovirology, and disease susceptibility
We have a strong interest in understanding the impacts of koala retrovirus (KoRV) on koala immunology and disease susceptibility.
Works
Search Professor Jake O'Donnell’s works on UQ eSpace
2024
Journal Article
HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
Tardiota, Nicolas, Jaberolansar, Noushin, Lackenby, Julia A., Chappell, Keith J. and O’Donnell, Jake S. (2024). HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors. Virology Journal, 21 (1) 14. doi: 10.1186/s12985-024-02288-z
2024
Journal Article
Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease
O’Donnell, Jake S., Jaberolansar, Noushin and Chappell, Keith J. (2024). Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease. The Lancet Microbe, 5 (4), e400-e408. doi: 10.1016/s2666-5247(23)00359-2
2023
Journal Article
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma
O'Donnell, Jake S., Hunt, Stewart K. and Chappell, Keith J. (2023). Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma. The Lancet Haematology, 10 (7), e539-e548. doi: 10.1016/S2352-3026(23)00087-X
2022
Journal Article
Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine
O’Donnell, Jake S., Isaacs, Ariel, Jakob, Virginie, Lebas, Celia, Barnes, James B., Reading, Patrick C., Young, Paul R., Watterson, Daniel, Dubois, Patrice M., Collin, Nicolas and Chappell, Keith J. (2022). Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine. Frontiers in Immunology, 13 976968, 976968. doi: 10.3389/fimmu.2022.976968
2021
Journal Article
Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?
O’Donnell, Jake S. and Chappell, Keith J. (2021). Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)?. Frontiers in Microbiology, 12 724654, 1-4. doi: 10.3389/fmicb.2021.724654
2020
Journal Article
Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma
Lepletier, Ailin, Madore, Jason, O'Donnell, Jake S., Johnston, Rebecca L., Li, Xian-Yang, McDonald, Elizabeth, Ahern, Elizabeth, Kuchel, Anna, Eastgate, Melissa, Pearson, Sally-Ann, Mallardo, Domenico, Ascierto, Paolo A., Massi, Daniela, Merelli, Barbara, Mandala, Mario, Wilmott, James S., Menzies, Alexander M., Leduc, Charles, Stagg, John, Routy, Bertrand, Long, Georgina V., Scolyer, Richard A., Bald, Tobias, Waddell, Nicola, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2020). Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma. Clinical Cancer Research, 26 (14), 3671-3681. doi: 10.1158/1078-0432.ccr-19-3925
2020
Journal Article
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
Chew, Hui Yi, De Lima, Priscila O., Gonzalez Cruz, Jazmina L., Banushi, Blerida, Echejoh, Godwins, Hu, Lingbo, Joseph, Shannon R., Lum, Benedict, Rae, James, O'Donnell, Jake S., Merida de Long, Lilia, Okano, Satomi, King, Brigid, Barry, Rachael, Moi, Davide, Mazzieri, Roberta, Thomas, Ranjeny, Souza-Fonseca-Guimaraes, Fernando, Foote, Matthew, McCluskey, Adam, Robinson, Phillip J., Frazer, Ian H., Saunders, Nicholas A., Parton, Robert G., Dolcetti, Riccardo, Cuff, Katharine, Martin, Jennifer H., Panizza, Benedict, Walpole, Euan ... Simpson, Fiona (2020). Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies. Cell, 180 (5), 895-914.e27. doi: 10.1016/j.cell.2020.02.019
2019
Conference Publication
Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+T cells (PD1tR) driven by tumour CD155
de Oliveira, A. Lepletier, Madore, J., O'donnell, S., Johnston, R. L., Eastgate, M., Mallardo, D., Ascierto, P. A., Massi, D., Merelli, B., Mandala, M., Wilmott, J. S., Bald, T., Stagg, J., Routy, B., Long, G. V., Scolyer, R. A., Waddell, N., Dougall, W. C., Teng, M. W. L. and Smyth, M. (2019). Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+T cells (PD1tR) driven by tumour CD155. Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11-14 December 2019. Oxford, United Kingdom: Oxford University Press.
2019
Journal Article
The promise of neoadjuvant immunotherapy and surgery for cancer treatment
O'Donnell, Jake S., Hoefsmit, Esmee P., Smyth, Mark J., Blank, Christian U. and Teng, Michele W.L. (2019). The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clinical Cancer Research, 25 (19), 5743-5751. doi: 10.1158/1078-0432.CCR-18-2641
2019
Journal Article
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, Jake S., Teng, Michele W. L. and Smyth, Mark J. (2019). Cancer immunoediting and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology, 16 (3), 151-167. doi: 10.1038/s41571-018-0142-8
2019
Journal Article
Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome
Liu, Jing, O’Donnell, Jake S., Yan, Juming, Madore, Jason, Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2019). Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. OncoImmunology, 8 (5) e1581530, 1-12. doi: 10.1080/2162402X.2019.1581530
2018
Journal Article
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
Ahern, Elizabeth, Harjunpää, Heidi, O'Donnell, Jake S., Allen, Stacey, Dougall, William C., Teng, Michele W. L. and Smyth, Mark J. (2018). RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. OncoImmunology, 7 (6) e1431088, e1431088. doi: 10.1080/2162402X.2018.1431088
2018
Journal Article
Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
Liu, Jing, Rozeman, Elisa A., O’Donnell, Jake S., Allen, Stacey, Fanchi, Lorenzo, Smyth, Mark J., Blank, Christian U. and Teng, Michele W. L. (2018). Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. OncoImmunology, 8 (2) e1546068, 1-10. doi: 10.1080/2162402X.2018.1546068
2017
Journal Article
Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
Glodde, Nicole, Bald, Tobias, van den Boorn-Konijnenberg, Debby, Nakamura, Kyohei, O'Donnell, Jake S., Szczepanski, Sabrina, Brandes, Maria, Eickhoff, Sarah, Das, Indrajit, Shridhar, Naveen, Hinze, Daniel, Rogava, Meri, van der Sluis, Tetje C., Ruotsalainen, Janne J., Gaffal, Evelyn, Landsberg, Jennifer, Ludwig, Kerstin U., Wilhelm, Christoph, Riek-Burchardt, Monika, Müller, Andreas J., Gebhardt, Christoffer, Scolyer, Richard A., Long, Georgina V., Janzen, Viktor, Teng, Michele W. L., Kastenmüller, Wolfgang, Mazzone, Massimiliano, Smyth, Mark J., Tüting, Thomas and Hölzel, Michael (2017). Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 47 (4), 789-802. doi: 10.1016/j.immuni.2017.09.012
2017
Journal Article
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
O'Donnell, Jake S., Massi, Daniela, Teng, Michele W. L. and Mandala, Mario (2017). PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Seminars in Cancer Biology, 48, 91-103. doi: 10.1016/j.semcancer.2017.04.015
2017
Journal Article
Resistance to PD1/PDL1 checkpoint inhibition
O'Donnell, Jake S., Long, Georgina V., Scolyer, Richard A., Teng, Michele W. L. and Smyth, Mark J. (2017). Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 52, 71-81. doi: 10.1016/j.ctrv.2016.11.007
2016
Journal Article
Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease
Liu, Jing, Blake, Stephen J., Yong, Michelle C. R., Harjunpaa, Heidi, Ngiow, Shin Foong, Takeda, Kazuyoshi, Young, Arabella, O'Donnell, Jake S., Allen, Stacey, Smyth, Mark J. and Teng, Michele W. L. (2016). Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discovery, 6 (12), 1382-1399. doi: 10.1158/2159-8290.CD-16-0577
2016
Journal Article
The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer
Pera, Elena, Kaemmerer, Elke, Milevskiy, Michael J. G., Yapa, Kunsala T. D. S., O'Donnell, Jake S., Brown, Melissa A., Simpson, Fiona, Peters, Amelia A., Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2016). The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer. Cancer Cell International, 16 (24) 24, 24. doi: 10.1186/s12935-016-0299-0
2015
Conference Publication
Calcium signalling and the acquisition of trastuzumab resistance in HER2 positive breast cancer cells
Kaemmerer, Elke, Pere, Elena, Peters, Amelia A., Yapa, Kunsala T. D. S., Simpson, Fiona, O'Donnell, Jake, Roberts-Thomson, Sarah J. and Monteith, Gregory R. (2015). Calcium signalling and the acquisition of trastuzumab resistance in HER2 positive breast cancer cells. APSA ASCEPT Joint Scientific Meeting 2015, Hobart, TAS Australia, 29 November - 2 December 2015.
Funding
Current funding
Supervision
Availability
- Dr Jake O'Donnell is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Preclinical development and clinical testing of a Human T lymphotropic virus type 1 (HTLV-1)-specific vaccine
Principal Advisor
Other advisors: Professor Keith Chappell, Dr Noushin Jaberolansar
-
Doctor Philosophy
Understanding vaccine-intrinsic factors which influence immunological memory and protection from disease
Associate Advisor
Other advisors: Professor Keith Chappell, Dr Noushin Jaberolansar
Media
Enquiries
For media enquiries about Dr Jake O'Donnell's areas of expertise, story ideas and help finding experts, contact our Media team: